Research progress of therapeutic vaccines for treating chronic hepatitis B
Hepatitis B virus (HBV) is a member of Hepadnavirus family, which leads to chronic infection in around 5% of patients with a high risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma. Despite the availability of prophylactic vaccines against hepatitis B for over 3 decades,...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-05-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2016.1276125 |
| _version_ | 1797674566195085312 |
|---|---|
| author | Jianqiang Li Mengru Bao Jun Ge Sulin Ren Tong Zhou Fengchun Qi Xiuying Pu Jia Dou |
| author_facet | Jianqiang Li Mengru Bao Jun Ge Sulin Ren Tong Zhou Fengchun Qi Xiuying Pu Jia Dou |
| author_sort | Jianqiang Li |
| collection | DOAJ |
| description | Hepatitis B virus (HBV) is a member of Hepadnavirus family, which leads to chronic infection in around 5% of patients with a high risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma. Despite the availability of prophylactic vaccines against hepatitis B for over 3 decades, there are still more than 2 billion people have been infected and 240 million of them were chronic. Antiviral therapies currently used in the treatment of CHB (chronic hepatitis B) infection include peg-interferon, standard α-interferon and nucleos/tide analogs (NAs), but none of them can provide sustained control of viral replication. As an alternative strategy, therapeutic vaccines for CHB patients have been widely studied and showed some promising efficacies in dozens of preclinical and clinical trials. In this article, we review current research progress in several types of therapeutic vaccines for CHB treatment, including protein-based vaccines, DNA-based vaccines, live vector-based vaccines, peptide-based vaccines and cell-based therapies. These researches may provide some clues for developing new treatments in CHB infection. |
| first_indexed | 2024-03-11T22:00:53Z |
| format | Article |
| id | doaj.art-ada7f3eff08f4f9ba86eceed35a06111 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:00:53Z |
| publishDate | 2017-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-ada7f3eff08f4f9ba86eceed35a061112023-09-25T11:00:55ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2017-05-0113598699710.1080/21645515.2016.12761251276125Research progress of therapeutic vaccines for treating chronic hepatitis BJianqiang Li0Mengru Bao1Jun Ge2Sulin Ren3Tong Zhou4Fengchun Qi5Xiuying Pu6Jia Dou7Jiangsu Theravac Bio-pharmaceutical Co., Ltd.Jiangsu Theravac Bio-pharmaceutical Co., Ltd.Jiangsu Theravac Bio-pharmaceutical Co., Ltd.Jiangsu Theravac Bio-pharmaceutical Co., Ltd.Jiangsu Theravac Bio-pharmaceutical Co., Ltd.Jiangsu Theravac Bio-pharmaceutical Co., Ltd.School of Life Science and Engineering, Lanzhou University of TechnologyDalian Institute for Drug ControlHepatitis B virus (HBV) is a member of Hepadnavirus family, which leads to chronic infection in around 5% of patients with a high risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma. Despite the availability of prophylactic vaccines against hepatitis B for over 3 decades, there are still more than 2 billion people have been infected and 240 million of them were chronic. Antiviral therapies currently used in the treatment of CHB (chronic hepatitis B) infection include peg-interferon, standard α-interferon and nucleos/tide analogs (NAs), but none of them can provide sustained control of viral replication. As an alternative strategy, therapeutic vaccines for CHB patients have been widely studied and showed some promising efficacies in dozens of preclinical and clinical trials. In this article, we review current research progress in several types of therapeutic vaccines for CHB treatment, including protein-based vaccines, DNA-based vaccines, live vector-based vaccines, peptide-based vaccines and cell-based therapies. These researches may provide some clues for developing new treatments in CHB infection.http://dx.doi.org/10.1080/21645515.2016.1276125chronic hepatitis bhepatitis b virustherapeutic vaccine |
| spellingShingle | Jianqiang Li Mengru Bao Jun Ge Sulin Ren Tong Zhou Fengchun Qi Xiuying Pu Jia Dou Research progress of therapeutic vaccines for treating chronic hepatitis B Human Vaccines & Immunotherapeutics chronic hepatitis b hepatitis b virus therapeutic vaccine |
| title | Research progress of therapeutic vaccines for treating chronic hepatitis B |
| title_full | Research progress of therapeutic vaccines for treating chronic hepatitis B |
| title_fullStr | Research progress of therapeutic vaccines for treating chronic hepatitis B |
| title_full_unstemmed | Research progress of therapeutic vaccines for treating chronic hepatitis B |
| title_short | Research progress of therapeutic vaccines for treating chronic hepatitis B |
| title_sort | research progress of therapeutic vaccines for treating chronic hepatitis b |
| topic | chronic hepatitis b hepatitis b virus therapeutic vaccine |
| url | http://dx.doi.org/10.1080/21645515.2016.1276125 |
| work_keys_str_mv | AT jianqiangli researchprogressoftherapeuticvaccinesfortreatingchronichepatitisb AT mengrubao researchprogressoftherapeuticvaccinesfortreatingchronichepatitisb AT junge researchprogressoftherapeuticvaccinesfortreatingchronichepatitisb AT sulinren researchprogressoftherapeuticvaccinesfortreatingchronichepatitisb AT tongzhou researchprogressoftherapeuticvaccinesfortreatingchronichepatitisb AT fengchunqi researchprogressoftherapeuticvaccinesfortreatingchronichepatitisb AT xiuyingpu researchprogressoftherapeuticvaccinesfortreatingchronichepatitisb AT jiadou researchprogressoftherapeuticvaccinesfortreatingchronichepatitisb |